Page 13 - Pharma Industry

Traditional system of medicines gaining worldwide acceptance: Sonowal

Union minister Sarbananda Sonowal on Saturday said traditional medicines like Ayush have gained a new lease of life, and are being recognised worldwide for their efficacy. He also said that the traditional medicine sector of India has grown beyond geographical boundaries and reached a global market, under the BJP-led central government. The Union Minister of Ayush was speaking after inaugurating a centre of excellence at the State Ayurvedic College and Hospital here. "Under the leadership of Prime Minister Narendra Modi, India has taken leadership position in the revamp of traditional medicines worldwide... This has helped our traditional medicine sector to grow out of its regular geography and communities to reach a wider population across communities from different parts of the world," Sonowal said. He said prior to 2014, the market value of Ayush products in India was limited to Rs 24,000 crore. But now, the country's Ayush products have gained a market of Rs 4.50 lakh crore ..

Zydus Lifesciences gets USFDA nod for generic drug to prevent chest pain

Zydus Lifesciences Ltd on Friday said it has received final approval from the US health regulator to manufacture and market its generic Isosorbide Mononitrate extended-release tablets used to prevent chest pain in patients with a certain heart condition. The approval by the US Food and Drug Administration (USFDA) is to manufacture and market Isosorbide Mononitrate Extended-Release, of strengths 30 mg, 60 mg, and 120 mg, Zydus Lifesciences said in a regulatory filing. Isosorbide mononitrate is used to prevent chest pain (angina) in patients with a certain heart condition, coronary artery disease, it added. The product will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, the company said. Isosorbide Mononitrate extended-release tablets 30 mg, 60 mg, and 120 mg had annual sales of USD 47 million in the US, Zydus said citing IQVIA December 2023 data. PTI RKL.

India's stand on IPRs, pharma help promote growth of generic industry: GTRI

India's stand on intellectual property rights (IPRs) and pharma issues in proposed trade agreements balances innovation with public health needs, ensures availability of affordable medicines and promotes growth of generic medicine industry, a GTRI report said on Friday. Think tank Global Trade Research Initiative (GTRI) said that by opposing demands of developed nations on issues like 'data exclusivity' and 'patent linkage' in free trade agreements (FTAs), India ensures that generic drug manufacturers get greater market access and cost of life-saving medicines gets reduced significantly. "India's approach underscores a commitment to balancing innovation with public health needs, adopting a flexible interpretation of TRIPS to align with its developmental goals, and preventing the establishment of unfair monopolies, especially in the pharmaceutical sector," the GTRI paper said. It added that this stance reflects a broader effort to protect traditional knowledge and ensure the ...

Govt rejects EU FTA's data exclusivity demand to protect drug cos' interest

India on Thursday said it has rejected the demand of the four European nations EFTA bloc for inclusion of a 'data exclusivity' provision in proposed free trade agreements, stating that it always protects the interests of the domestic generic drugs industry. Commerce Secretary Sunil Barthwal said there is no Free Trade Agreement (FTA) in which India will go against the generic drug industry. The European Free Trade Association (EFTA) members are Iceland, Liechtenstein, Norway, and Switzerland. The bloc is negotiating a trade agreement with India. "They want that there should be data exclusivity, we rejected their demand. We are with our generic industry. "There is no fear for Indian generic industry (from this agreement). In fact, it is our very important objective to see that generic drug industry flourishes," he told reporters here. The secretary said the industry is contributing significantly to India's exports, which are also growing. "So we are there to protect the interest o

Natco Pharma Q3 results: Net profit rises over 3-fold to Rs 212.7 crore

Natco Pharma Ltd on Wednesday reported over three-fold rise in consolidated net profit at Rs 212.7 crore in the third quarter ended December 31, 2023 on the back of robust revenue growth. The company had posted a consolidated net profit of Rs 62.3 crore in the same period last fiscal, Natco Pharma said in a regulatory filing. Consolidated revenue from operations in the quarter under review stood at Rs 758.6 crore, as against Rs 492.5 crore in the year-ago period, it added. Total expenses were higher at Rs 539.3 crore, up from Rs 431.9 crore in the same quarter last fiscal, the company said. There was strong growth across businesses compared to last year, Natco said, adding it is confident of its strategy going forward. Revenue from export of formulations was at Rs 605.6 crore in the third quarter, up from Rs 333.7 crore in the year-ago period. However, domestic formulations revenue was down at Rs 99.4 crore, as compared to Rs 101.1 crore in the corresponding period last fiscal, i

Wockhardt Q3 results: Loss narrows to Rs 86 cr, revenue up marginally

Pharmaceuticals firm Wockhardt Ltd on Wednesday reported narrowing of consolidated net loss to Rs 86 crore for the third quarter ended December 31, 2023. The company had incurred a loss of Rs 102 crore in the third quarter last fiscal, Wockhardt Ltd said in a regulatory filing. Revenue from operations during the quarter under review stood at Rs 701 crore as compared to Rs 699 crore in the year-ago period, the company said. Total expenses were lower at Rs 796 crore as against Rs 803 crore in the same period last fiscal.

Zydus Lifesciences Q3 result: Net profits rise by 27%, beat estimates

Indian generic drugmaker Zydus Lifesciences reported a bigger-than-expected rise in third-quarter profit on Friday, driven by strong sales in its domestic and overseas markets

Biocon Biologics partners with Sandoz Australia to sell cancer drugs

The partnership will provide Sandoz the exclusive rights to promote, sell, and distribute biosimilar Trastuzumab and biosimilar Bevacizumab in Australia

Biocon inks pact with Sandoz for sale of 2 biosimilar products in Australia

Biocon Biologics on Friday said it has inked a five-year pact with pharmaceutical company Sandoz AG regarding the sale and distribution of two cancer treatment biosimilar products in Australia. The agreement provides Sandoz the exclusive rights to promote, sell and distribute biosimilars Trastuzumab and Bevacizumab in Australia, Biocon Biologics said in a statement. Biocon Biologics is a subsidiary of Biocon Ltd. Under the agreement, Sandoz will distribute the Biocon Biologics' brands, Ogivri (Trastuzumab) and Abevmy (Bevacizumab), and facilitate the sustained access of these medications that were previously distributed by another pharmaceutical company to patients in Australia. Trastuzumab is a biosimilar of Herceptin and Bevacizumab is a biosimilar of Avastin and utilised for the treatment of various cancers. "Following the recent establishment of our strategic partnership with Sandoz in Japan, our agreement with Sandoz in Australia marks another important milestone of our globa

JB Pharma CEO attributes 3.5% of company's growth to new introductions

"We are growing at 16 per cent, compared to the Indian Pharma Market (IPM) growth of 8 per cent, and a 12 per cent growth of the market which we cover," Chopra said

Lupin Q3 results: Net jumps 300% to Rs 613 cr on back of record sales

Nilesh Gupta, MD, Lupin Limited said, "We delivered our highest quarterly sales to date, crossed the Rs 5,000 crore mark for the first time, driven by strong growth across geographies."

Novo Nordisk buys three plants for $11 billion to boost Wegovy output

Novo's biggest shareholder is buying Catalent Inc., one of the world's biggest drug-manufacturing companies, for $16.5 billion, including debt. In a three-way arrangement

Alembic Pharma Q3 results: Profit up 48% as raw material cost declines

This increase in PAT was attributed to tax deduction, decline in the cost of materials consumed, and improvement in Ebitda

Torrent Pharma Q3 results: Profit after tax up 51% at Rs 443 crore

Torrent Pharmaceuticals' share price rose by 0.51 per cent, ending the day's trade at Rs 2,524 apiece on the Bombay Stock Exchange (BSE)

Sun Pharma Q3 results: Net profit up 16.5% at Rs 2,524 cr on US, India biz

Bloomberg analysts' estimates had pegged the revenue at Rs 12,336 crore and PAT at Rs 2,470 crore

Sun Pharma Q3 results: Net profit increases 15% at Rs 2,524 crore

Sales in its US formulations business rose nearly 15 per cent to Rs 3,974 crore, while sales from its India formulations rose more than 11 per cent to Rs 3,779 crore

Pharmeasy FY23 losses widen 31%, revenue increases 16% to Rs 6,644 cr

Online pharmacy dropped plan for an IPO in 2022, says it is cutting down expenses

Breather for consumers as drug prices likely to remain same this year

In previous two years, hikes were in the range of 10-12%

Indian firms corner more of growing pharma market as MNCs go niche

Indian drug firms are focussing on expanding their salesforce and distri­bution, while getting into trade generics to garner volumes

Govt committed to transform healthcare landscape: Health minister Mandaviya

The government is committed to transform the country's entire healthcare landscape, Health Minister Mansukh Mandaviya said Wednesday, highlighting that this dispensation opened several new AIIMS, raised the number of medical colleges to almost double and operationalised more than 10,000 Jan Aushadhi Kendras. He was speaking after virtually inaugurating a Super Specialty Block at Ganesh Shankar Vidyarthi Memorial Medical College in Kanpur, Uttar Pradesh. He also laid the foundation stone of an All India Institute of Speech and Hearing (AIISH) Satellite Centre in Kanpur. "This Super Specialty Block offering 12 super-specialty services will help people take these specialised services locally, saving their valuable time and resources," he said. On the AIISH Centre in Kanpur, he said it will be the first such state-of-the-art centre in North India which will not only train doctors but also provide care to people. It is the dream of Prime Minister Narendra Modi that AIISH institutes be .